Genentech has a strong reputation in San Francisco's venture capital circles, after all, it has soared from $400,000,000 to more than $100 million in less than four years, and is on the track to go public.

Suffice it to say, if you don't know Genentech, you are not qualified to say that you are a practitioner in the venture capital industry.

But when the news came out that Polaris Capital had acquired Genentech and suspended the listing process, it immediately shocked the whole circle, and they inquired about the details.

When they learned that Polaris Capital had given a minimum valuation of $200 million, they were all shocked by Polaris Capital's generosity.

Of course, there are also people with sour hearts who secretly satirize Polaris Capital for being brainless and offering such a high price.

But no matter what they think, at least one thing is certain.

Polaris Capital rushed into this circle with an extremely strong attitude, and all capital companies in San Francisco knew that this market had another rampaging crocodile.

What do the outside world and peers think, Xia Yu didn't have the heart to care, after ending the acquisition of Genentech, he told Peter Lynch to continue recruiting, and then he hurried to start the second action.

Time is urgent, and he must act quickly to avoid the cake being eaten by others!

This time, he plans to make a big one, to make Polaris Capital famous in one fell swoop, and at the same time to lay an optimus prime for his strategy in the field of biopharmaceuticals.

Genentech has the future.

It only cost him more than 100 million US dollars, and at this pace, he wants to spend most of the money in his hands, but he doesn't know that it will be until the Year of the Monkey, and only one of the giants of biopharmaceuticals can digest a little.

This goal is the famous Abbott company in later generations.

In the 80s, it was still the era of oil, and among the top ten companies in the United States, oil companies accounted for half of the country.

But in the 90s, it will be the time when the biopharmaceutical field explodes.

At that time, it will be too late to enter again, and now is definitely the right time to enter early.

Because now, the biopharmaceutical field has not yet exploded, and even the giants in the industry have a low market capitalization, not even a 10 billion dollar level.

It is worth mentioning that the company with the highest market value in the United States is none other than the blue giant IBM, with a market value of more than $30 billion.

Back to the topic, let's talk about the biopharmaceutical field.

At this time, there were not a few pharmaceutical giants in the United States, and the first one was not Johnson & Johnson, which was the first in the future, but Merck, which had a market value of more than 200 billion US dollars in the later generations, and Johnson & Johnson ranked second.

Next, there are Eli Lilly, Bristol-Myers Squibb, Pfizer, Wyeth, Abbott and other companies.

That's right, although Pfizer is already strong at this time, it is not the three global pharmaceutical giants in later generations, and Wyeth has not been acquired by Pfizer.

Among these companies, Xia Yu is eyeing Abbott, which ranks ninth in the U.S. pharmaceutical field at this time.

Johnson & Johnson has a market value of more than $300 billion in later generations, once exceeding $400 billion, and Pfizer is also hovering at $200 billion or 300 billion.

But in fact, Xia Yu passed the two after thinking about it.

There is no way, Johnson & Johnson is behind a big consortium, he can't afford to provoke it, at this time Johnson & Johnson is developing well, and a consortium that is not bad for money will not sell it.

As for Pfizer, a Viagra became popular all over the world in later generations, but at this time, it was still more than ten years before Viagra was developed.

Moreover, Xia Yu also knows that the market value of Pfizer in the future is very high, but the high market value is piled up with huge capital, and Pfizer can sit in that position completely by mergers and acquisitions, otherwise the viagra drug alone will not be able to support this height.

Since 1999, Pfizer has acquired Warner Lambert, Famacia, and Wyeth with huge sums of money, and obtained a large number of high-quality brand drugs, each of which can be ranked in the top 10 in the history of pharmaceutical mergers and acquisitions, with a total value of 244.1 billion US dollars!

Among them, the acquisition of Warner Lambert Company, before Xia Yu's rebirth, was the largest acquisition in the history of pharmaceuticals!

Leaving aside posterity, the current Pfizer company is also immersed in diversification and cannot extricate itself, constantly acquiring companies, and in the eyes of the outside world, Pfizer cannot be called a qualified pharmaceutical company.

Because Pfizer invests only 5 percent in scientific research, far less than 9 percent of Merck and Johnson & Johnson.

Pfizer's demise was ten years, and it was not until the lack of scientific research results and the shortcomings of new drugs became apparent that it woke up and reinvested heavily in the research and development of new drugs, which led to the successful launch of Viagra in 1998.

So at this time, Xia Yu doesn't want to mess with Pfizer.

Pfizer, which has been thinking about buying and buying, will not necessarily accept his acquisition.

In that case, why should he be thankless?

There is still a long time ahead, and there will always be a suitable opportunity to do it again!

As for why other companies don't choose, they want to choose Abbott, because in addition to Johnson & Johnson, Abbott has the greatest potential!

In the second half of this year, Abbott's George W. Dr. B. Ratman would leave and found Amgen, the billionaire of what would become a billionaire, and Amgen would become one of the top 10 pharmaceutical companies in the United States.

Then in 2011, Abbott spun off an AbbVie company from the inside, and the market value broke 100 billion US dollars after being listed separately, becoming one of the top ten pharmaceutical companies in the United States.

As for Abbott itself, its market value is also more than 100 billion US dollars, and it is in the sixth or seventh place of American pharmaceutical companies before AbbVie.

Careful calculations show that Abbott, which now has a market value of only $2.8 billion, has been able to create three companies with more than $100 billion because of it, occupying three positions among the top ten pharmaceutical companies in the United States.

If the three companies are combined, their market value will exceed that of Johnson & Johnson, the strongest pharmaceutical company in the United States in the future.

And these three companies do not rise by mergers and acquisitions like Pfizer, but develop step by step, although they will also merge and acquire halfway, but they are mainly engaged in their own research and development development.

The potential is no worse than that of Johnson & Johnson, and now its market capitalization is much lower than that of Johnson & Johnson, the focus is that it is not controlled by the top ten consortia in the United States, and the difficulty of acquisition is much lower than that of Johnson & Johnson.

Xia Yu didn't choose it unless he was stupid!

Moreover, Abbott is not only great in the pharmaceutical field, but also in the field of milk powder, and is one of the three giants in the US milk powder market today.

In the milk powder market in the United States, the three giants are Wyeth Group, Abbott and Mead Johnson, and the next largest is Garbo and the like.

Wyeth Group has overpowered Abbott in both the pharmaceutical field and the milk powder field, but Xia Yu has not considered acquiring Wyeth Group.

In any industry, it is less difficult and expensive to acquire the second child.

Strictly speaking, Abbott is not so much a pharmaceutical company as it is a healthcare company, because its products are in the fields of nutraceuticals, medicines, medical devices, diagnostic instruments and reagents.

After determining the target, Xia Yu immediately convened a high-level meeting of the company, set up an acquisition team again, and made every effort to make an acquisition plan.

At the same time, considering that the number of companies at this time was far from sufficient due to the series of actions that followed, Xia Yu once again urged Korn Ferry to recruit elites with M&A experience in biopharmaceutical, finance, media and high-tech fields for Polaris Capital.

The acquisition of Abbott is a major task, but it is definitely not the only one!

()